Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
This article was originally published in The Pink Sheet Daily
Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.
You may also be interested in...
Sanofi’s Praluent Closes Gap On Repatha In Europe, As GSK Gets Green Light For World’s First Malaria Vaccine
Europe’s CHMP grants positive opinions for Sanofi’s Praluent and GSK’s not-for-profit malaria vaccine Mosquirix at July meeting; other products recommended include Shire’s Intuniv, Merck’s Zerbaxa, Basilea’s Cresemba and Keryx’s Fexeric.
Firm adds third antifungal to its portfolio.
Astellas Pharma US expects oncology will account for 40% of sales in three years, becoming its top business segment – significant growth for a company that just four years ago had no commercial presence in oncology. The plans rely heavily on Xtandi, suggesting it might be time to ramp up business development activity.